On average, 98 percent of pharmaceutical experimental research projects, including the time, materials, and brainpower deployed in the quest for novel medicines, fail to reach patients. This costs the industry billions in R&D investment annually and delays new medicines for patients in need.
The number one challenge we face is that despite technology making it easy to generate a tremendous amount of data and information, we’re not very good (yet) at understanding or connecting to knowledge about how disease biology works—and this is why so many drugs fail in clinical trials.
The increasing complexity of disease biology makes finding novel discoveries challenging. Scientists have been underserved for decades, without major advancements in tools and technology to efficiently navigate the magnitude of scientific data and evidence available to them. BenchSci, a world leader in AI solutions for drug discovery, is exponentially improving the speed and quality of life saving research and development through their ASCEND platform.
“Our vision is to help bring hope to patients faster. Our role in solving this enormous challenge is to develop and train technology that can change the world through the eyes and minds of scientists,” said Liran Belenzon, CEO and Co-Founder of BenchSci.
ASCEND empowers scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early to move the most promising projects forward faster. The platform harnesses BenchSci's proprietary machine learning technology that is trained by scientists to extract experimental evidence from internal and external sources. Using curated ontology datasets, the platform makes connections across experiment outcomes to create the first commercially available, unbiased and evidenced-based map of the underlying biology of disease.
Today, thousands of scientists, 16 of the world’s top 20 pharma companies and 4,500 research facilities globally have leveraged BenchSci’s applications to drive efficiencies in experiment design, while advancing the speed and success of programs.
